Document is current
Any future updates will be listed below
-
Authors
Ye, Shiqi
Xu, Wenhao
Chen, Zheqi
Zhu, Chuanying
Ge, Qintao
Lu, Jiahe
Chang, Kun
Tian, Xi
Anwaier, Aihetaimujiang
Zhu, Shuxuan
Zhou, Siqi
Zhang, Wei
Wang, Yue
Zhao, Jianyuan
Li, Lingling
Shi, Yan
Cai, Tingting
Xu, Danfeng
Zhou, Xiangyu
Ye, Dingwei
Zhang, Hailiang
-
Funding
Funding for this research was provided by:
Shanghai Anticancer Association EYAS PROJECT (SACA-CY23A02)
Shanghai Anticancer Association EYAS PROJECT (SACA-CY23C04)
National Natural Science Foundation of China (82403377)
National Natural Science Foundation of China (81870285)
Beijing Xisike Clinical Oncology Research Foundation (Y-Young2024-0138)
Beijing Xisike Clinical Oncology Research Foundation (Y-HR2020MS-0948)
China Postdoctoral Science Foundation (2024M750538)
China Postdoctoral Science Foundation (GZC20230500)
Shanghai Municipal Health Bureau (2020CXJQ03)
China Anti-Cancer Association-Hengrui PARP Nicotinamide Cancer Research Fund (CETSDHRCORP252-4-021)
- License Information
-
More Information
Article History
Received: 17 February 2025
Accepted: 23 July 2025
First Online: 21 October 2025
Declarations
:
: Our research complies with all relevant ethical regulations and guidelines. The study design and procedures were conducted in accordance with the principles of the Helsinki Declaration II. The Ethics approval and consent to participate of the Urology and Pathology departments in this study were approved by the Institutional Review Board (IRB) of FUSCC (No. 050432-4-2307E). All animal procedures were performed following protocols approved by the Ethical Committee of FUSCC and in accordance with guidelines from the IACUC of FUSCC (FUSCC-IACUC-S2024-0073).
: The authors declare no competing interests.
